The AstraZeneca, Sinopharm and Eli Lilly-backed oncology drug developer has revealed its intention to go public in a Hong Kong IPO that could reportedly fetch $250m.
Abbisko Therapeutics, a China-based cancer treatment developer backed by pharmaceutical firms AstraZeneca, Sinopharm and Eli Lilly, has filed for an initial public offering in Hong Kong, AVCJ reported on Wednesday.
The company could raise about $250m through the offering, according to a Bloomberg report citing sources familiar with the matter.
Founded in 2016, Abbisko is developing small molecule, precision therapies and immuno-oncology therapies for multiple types of cancer. It has exclusive licence agreements in place with pharmaceutical companies including X4…
